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Abstract
Probiotics are microorganisms that live in symbiosis with the human body. 
The intake of probiotics in adequate amounts can improve biological functions 
bringing improvements in the health of the host. Many studies have demonstrated 
the indisputable antimicrobial activity of probiotics and their potential for an 
alternative treatment of infections. Nevertheless, the forms of encapsulation, as 
well as clinical trials on the clinical use of these microorganisms as a recognized and 
well-established protocol, are still incipient. In this chapter, we provide a general 
approach to the topic and point to future directions in the probiotics field for this 
purpose. Moreover, microbial resistance is a current public health problem and 
the search for new therapeutic alternatives is urgent. Probiotics and other natural 
therapies have been considered very promising. The approaches of future research 
should focus mainly on the isolation of new probiotic microorganisms, the defini-
tion of inoculum, forms of encapsulation for controlled delivery, and clinical trials 
for the definition of doses and mechanism of action in the fight against infections.
Keywords: probiotics, pharmacology, antimicrobial activity, microbiota, 
biomaterials
1. Introduction
The human body is inhabited by numerous microorganisms, including bacteria, 
fungi, viruses, and protozoa, which represent the human microbiota. Compared to 
the number of human cells, there is a much larger number of microorganisms [1], 
which affect the host’s physiological functions in different ways [2]. After a long 
time of science focusing on pathogenic microorganisms that cause human diseases, 
the interest was also turned to those that provide benefits to the organism, such as 
probiotics.
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The first time that probiotics were mentioned and defined was in 1965 and the 
concept was restricted to substances produced by bacteria that promote the growth 
of other bacteria [3]. In 2001, the Food and Agriculture Organization of the United 
Nations (FAO) updated the concept of probiotics for any living microorganisms 
that provide health benefits to the host when ingested in adequate quantities [4]. 
The most widely used and studied probiotics for human health benefits are gener-
ally gram-positive bacteria that function primarily as modulators and maintainers 
of gut health [5]. Examples of widely studied probiotics such as Lactobacillus, 
Bifidobacterium, Escherichia, Enterococcus, Bacillus e Streptococcus [6].
The commensal intestinal microbiota is related to important functions for 
maintaining the health of the organism, such as increased resistance against 
infections, differentiation of the immune system, and synthesis of nutrients [7]. 
Nevertheless, recent studies have shown that the benefits of probiotics for human 
health go beyond [8], including anti-inflammatory activities [9], anti-tumor activi-
ties [10], antioxidant [11], antimicrobial [12] and modulation of the microbiome 
[13]. Although, research on the antimicrobial activity of probiotic microorganisms 
remains incipient and its clinical applicability for the treatment of infections has 
not been fully explored [14].
Infections have been commonly treated with antibiotics. However, the unre-
strained and irrational use of these drugs can range from individual harms, such 
as specific adverse effects of the drug for the patient, to serious public health 
problems, such as the selection of drug-resistant microorganisms [15]. Likewise, 
research on alternative therapies for the treatment of infectious diseases should be 
encouraged and the field of probiotic microorganisms is very promising. Therefore, 
in this chapter, we will discuss the current reality of treating infections using 
probiotic microorganisms and/or their by-products as well as the prospects for this 
therapy to become a reality in current medicine.
2. Probiotic microorganisms
In 1965, Lilly and Stillwell first used the term probiotic, describing sub-
stances that one organism secretes and can stimulate the growth of another [16]. 
Nonetheless, its use goes back to millennia, as the use of recipes with fermented 
milk by Greeks and Romans. There are also reports of the use of sour milk in the 
bible. Thus, it is observed that the benefits of the use of probiotics to human health 
have been discussed for millennia [17].
These microorganisms, when colonizing the gastrointestinal tract, interact 
directly with the cells of the immune system, playing an important role in the 
maintenance and balance of the immune system [18]. The mechanisms of action of 
probiotics are complex and, in most cases, likely, more than one mechanism occurs 
simultaneously. The main biological pathways of action include increased epithelial 
barrier, inhibition of microbial adhesion and competitive exclusion of pathogenic 
microorganisms in addition to the production of antimicrobial substances, modula-
tion of the immune system, maintenance of normal levels of short-chain fatty acids, 
and regulation of intestinal absorption of electrolytes [19].
The word “probiotic” comes from Greek and means “for life” [20]. Probiotics 
are viable live microorganisms, bacteria, and yeasts, which confer benefits to the 
health of the host when ingested in adequate concentration. Probiotic microorgan-
isms, in general, are part of the intestinal microflora, but can also be found in 
ecological environments. Many factors need to be considered before isolating a 
potential probiotic microorganism. Initially, it is necessary that the strain is not 
pathogenic and shows some type of behavior that reflects in biological activities 
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for the benefit of the host [21]. Besides, it is important to consider that the probi-
otic action is not universal for all species and does not work the same in all tissues 
of the body [22].
Lactic acid bacteria (Lactococcus, Lactobacillus, Streptococcus, and Enterococcus) 
are among the most well-known microorganisms, used and studied by man for 
probiotic purposes. In addition to these, we can include, Bifidobacterium and 
Saccharomyces species, a non-pathogenic yeast [23–25]. Table 1 summarizes the 
main probiotic microorganisms mentioned in the literature for the benefit of 
human health.
Microorganisms can produce lactic acid from different carbon sources, as well 
as release secondary metabolites, including bacteriocins, exopolysaccharides, and 
enzyme complexes with antimicrobial properties preventing the installation and 
growth of other microorganisms [21, 37]. The mechanisms involved in the action 
of these microbial products are well understood concerning the benefits generated 
to the human intestine. However, the use of probiotics for alternative antimi-
crobial therapy against infections, in general, is incipient, although promising. 
Subsequently, we will discuss how probiotics can affect a human microbiota, ways 
of encapsulation, and their main uses for treating infections.
3. Probiotics affect the microbiota
In recent years, several findings have revealed benefits in the administration 
of probiotics, ranging from direct inhibition of pathogenic microorganisms to 
improvements in host immune system functions [38–43].
Despite a large number of studies with probiotics, most efforts are focused on 
understanding the benefits for the intestinal health of the host. Probiotics can exert 
their antimicrobial activity through different mechanisms of action. Generally, it 
has been reported that these microorganisms control/kill the pathogenic microbiota 
through the production of inhibitory substances such as bacteriocins and hydrogen 
peroxide (capable of inhibiting Gram-negative and Gram-positive pathogenic 
bacteria); interference at adhesion sites; competition for nutrients in the microenvi-
ronment, among others [41, 42, 44, 45]. Besides, there is also the modulation of the 
immune system, which also plays a role in the control of infections, which can occur 
in several ways: increased non-specific phagocytic activity through the activation of 
macrophages [9, 45, 46].
Genus Specie Main source Reference
Lactobacillus L. casei, L. bulgaricus, L. 
acidophilus, L. rhamnosus, L. 
reuteri, L. pantarum and L. 
johnsonii
Dairy and human 
gastrointestinal tract
[26, 27]
Bifidobacterium B. animalis, B. bifidum, B. breve, B. 
infantis, B. lactis, B. longum
Human, Dog, Primate, 
Pig, Cow and Horse 
gastrointestinal tract
[28–30]
Streptococcus Streptococcus thermophilus Dairy [31, 32]
Enterococcus Enterococcus faecalis, Enterococcus 
faecium
Human, Cow and Pig 
gastrointestinal tract
[33–35]
Pediococcus Pediococcus pentosaceus, Pediococcus 
acidilactici
Dry quark and rice wine [36]
Table 1. 
Main probiotic microorganisms that are cited in the literature for human health benefits.
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Several probiotic species are widely used in research showing its benefits to the 
host [46, 47]. Among these benefits, antimutagenic properties [48], anticarcino-
genic properties [49–51], antidiarrheal drugs [52–54], system stimulation [55], 
prevention of atopic dermatitis [56–58], reduced blood cholesterol [59, 60].
Therefore, the use of probiotics has been considered a promising strategy for the 
prevention and control of various infectious diseases [38–40, 42, 43, 48, 61–63].
Some studies have also demonstrated the importance of probiotics relating to 
multidrug-resistant bacteria [64]. Multidrug-resistant bacteria, such as vancomycin 
resistant enterococcus (VRE), carbapenemase-producing enterobacteria (CPE), 
and extended-spectrum beta-lactamase (ESBL)-carrying strains, represent a major 
public health issue because they are potential pathogens associated with a high 
mortality rate [64, 65]. Prevention strategies could be based on the use of probiotics 
to prevent the colonization of the colon microbiota. Transient colonization with 
multidrug-resistant bacteria could result in the transfer of antibiotic resistance 
genes in commensals or potential pathogens, resulting in the persistence of the 
resistance gene in the microbiota, which could be responsible for an increased risk 
of lethal infection due to the delay in introducing an effective antibiotic [64, 66]. 
Surprisingly, clinical cases demonstrated that fecal transplantation was able to cause 
decolonization of microbiota of naturally resistant Extended Spectrum β-lactamase 
(ESBL) bacterial strains [67–69]. Furthermore, there are reports that the composi-
tion of the microbiota of hospitalized patients is related to the susceptibility to 
colonization with multiresistant bacteria. The use of probiotic microorganisms 
such as L. plantarum or L. fermentum reduced the colonization of resistant patho-
gens such as Acinetobacter baumannii, Pseudomonas aeruginosa or Candida albicans 
[70, 71]. Nevertheless, an in vitro study showed that the culture supernatants of 
Clostridium butyricum, C. difficile, Clostridium perfringens, Enterococcus faecium, and 
L. plantarum were able to suppress the growth and transmission of gene resistance 
of bacteria carrying ESBL and Carbapenemase-Producing Enterobacteriaceae 
(CPE) [64]. It is undeniable that both colonization by probiotics and the use of their 
by-products have great potential in the treatment and prevention of infections, 
however these properties are still scarcely explored.
Vancomycin-resistant enterococci (VRE) seem less adapted to survival in the 
intestinal microbiota. Thus, these pathogens are more susceptible to decoloniza-
tion when compared to other multiresistant bacteria. The intestinal microbiota in 
patients suffering from hematologic malignancies is less frequently colonized by 
VRE in the presence of Barnesiella [7]. In vivo evidence demonstrates that supple-
menting resident microbiota with Barnesiella or Lactobacillus paracasei CNCM 
I-3689 reduces VRE colonization in mice [72, 73]. In clinics, a case report showed 
VRE decolonization after fecal grafting for the treatment of C. difficile colitis [64].
The clinical use of probiotics in the treatment of infection is challenging the 
thinking of encapsulation for delivery. It is necessary to maintain the viability of 
these microorganisms long enough to compete with pathogenic microorganisms. 
Next, we’ll discuss different potential encapsulation modalities for delivery.
4. Biomaterials for encapsulation of probiotics
The drug delivery systems through liposomes, micelles, carbon nanotubes, 
and dendrimers allowed the increase of therapeutic efficacy, reduction of toxicity, 
sustained and controlled release [74, 75]. The biotechnology industry has been aim-
ing at the development of techniques for encapsulating probiotics, since their health 
benefits are indisputable. However, unlike inert substances, probiotics are live 
microorganisms, which in a way is a challenge in their manufacture, as they must be 
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kept in a live/viable state during the processing, storage, and gastrointestinal transit 
steps to ensure its effectiveness on target sites [75].
The encapsulation technique consists of a set of physical–chemical or mechani-
cal processes in which solid, liquid or gaseous materials are packaged, trapped in 
another material, usually hydrocolloidal materials, resulting in the formation of 
particles that vary in shape and size (from nanometer to millimeter) [76–78].
The encapsulated part is named core material, internal phase, active agent, or 
payload phase, and the encapsulating agent is called the carrier, shell, external 
phase, or matrix [78]. From these components, the encapsulation forms different 
structures: reservoir (where the core is surrounded by a shell), matrix (the internal 
phase is distributed on the surface), or coated matrix, in which matrix is sur-
rounded by an additional coating layer [78].
The use of nanoencapsulation techniques (<1 μm) is not feasible because of 
the size of the bacteria (1 to 5 μm) [76]. On the other hand, it is possible to obtain 
microcapsules using other techniques [79, 80]. The first microencapsulation tech-
niques applied were spray drying, freeze-drying or lyophilization, foam drying, and 
fluidized bed drying [78]. Other techniques used are extrusion, emulsion technolo-
gies, gel particles, coacervation, and electrospraying [76, 78, 81].
The encapsulation of probiotics can be made using natural polymers, such 
as polysaccharides, polypeptides, and polynucleotides, or synthetic polymers. 
Conventionally, three processes are involved in encapsulation. First, the cells must 
be incorporated into a matrix, which can be liquid (by dissolution or dispersion) 
or solid (by agglomeration or adsorption). Then the solution must be dispersed 
(liquids) or sprayed (solids) on the surface. The last process aims to stabilize the 
structure, through polymerization, gelling, solidification, evaporation, coacerva-
tion, or coalescence [79].
Before choosing the technique, it is necessary to consider some important 
criteria: the relationship between the composition of the material, type of 
bacteria, temperature and pH of the medium, as well as the host’s immune 
response. The biocompatibility of the material used in the encapsulation is 
directly related to the viability of the probiotics, which must remain equal to or 
greater than 107 CFU/ml [82, 83]. Therefore, factors such as solubility, digestibil-
ity, and release capacity must also be carefully analyzed [84]. Consequently, it is 
expected that the biomaterial will be able to form an effective protective barrier 
to resist pH variations and ensure the survival of bacteria, without causing 
damage to the host organism. Next, some biomaterials commonly used for the 
encapsulation of probiotics will be discussed.
4.1 Alginate
It is a natural polysaccharide composed of alginic acid (β-D-manuronic acid 
and L-gunoronic acid), obtained through some types of seaweed (laminaria). It 
is considered the most used material for the encapsulation of probiotics. Calcium 
alginate is preferable because it associates the biocompatibility of the material with 
a simple and low-cost technique. However, some disadvantages are attributed, such 
as the high porosity of the particles, which can reduce the protection of cells in the 
matrix [85] and sensitization in an acid medium [86]. Nonetheless, the association 
of alginate with other polymeric components or the addition of additives to the 
surface of the particles can easily overcome these defects [87]. Alginate spheres 
reach the intestine satisfactorily, without undergoing significant degradation by 
stomach acids [88]. Besides, the structural configuration of the probiotic encap-
sulation to alginate is comparable to the beneficial biofilm formation by probiotics 
bacteria [89].
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4.2 Chitosan
It is a biodegradable copolymer obtained from the deacetylation of chitin 
(polysaccharide) present in the crustacean exoskeleton. It consists of units of 
D-glucosamine, capable of forming polymeric networks through Cross-link due to 
the presence of free amino groups. It is commonly found associated with another 
polymer since studies have shown that its isolated use in the matrix does not 
contribute to the maintenance of cell viability [86]. When applied in multilayers 
together with calcium alginate, have shown promising results, where the particles 
are coated with chitosan forming polyelectrolyte complexes that reinforce the algi-
nate structure [89, 90]. Although its use is relatively common, care should be taken 
when choosing this biomaterial to encapsulate some types of bacteria, such as those 
from lactic acid, since chitosan can cause their inhibition [91]. Additionally, its 
solubility is directly related to the pH of the medium, being insoluble at pH higher 
than 5.5 [92], which may result in null or insufficient release.
4.3 Carrageenan
These natural polymers are extracted from red algae (Rhodophyceae) and are 
commonly used as additives in the food industry. Three variables are found: (kappa) 
k-carryenink, (iota) i-carrageenan and (lambda) λ-carrageenan [93]. The use for 
encapsulation of probiotics is based on the sol–gel transition characteristics of the 
types k-carrageenan and i-carrageenan [93]. The dissolution of the polymer occurs 
after heating in a temperature range between 40 and 45°C, at which point the 
bacteria must be incorporated. Subsequently, the solution is stored at room tem-
perature allowing gelation to occur, forming a three-dimensional gel [87]. Studies 
have shown that bacteria have been kept viable, demonstrating a promising effect 
of the use of carrageenan [94–96].
4.4 Gellan gum
This polysaccharide comes from the bacterium Sphingomonas elodea. It is com-
posed of glucose (60%), rhamnose (20%), and gluconic acid (20%). These micro-
bial polysaccharides are considered water-soluble polymers and are commonly used 
as solidifying, gelling, or stabilizing agents [97]. Other microbial polysaccharides, 
such as arabic gum, jamilam, and xanthan gum, when associated with gelam gum, 
become very promising for the encapsulation of probiotics [98].
4.5 Cellulose acetate phthalate (CAP)
They are polysaccharides derived from plants that have important char-
acteristics, such as insolubility at pH below 5 and solubility at pH above 6. 
Thus, it can be used effectively to enable encapsulated probiotics to reach the 
intestine and be released gradually without being altered by stomach pH [99]. 
CAP does not form a gel, therefore, it is used as a coating agent for other biomaterials.
4.6 Starches
Another polysaccharide extracted from plants. Resistance to degradation by 
pancreatic enzymes present in the small intestine is an interesting characteristic 
that justifies its use as a probiotic delivery agent, guaranteeing the viability of 
bacteria when reaching the large intestine [86, 100]. It is commonly associated with 
alginate or carrageenan to form resistant capsules or gels [87, 101].
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4.7 Synthetic polymers
The use of synthetic material for encapsulating probiotics requires that it must 
be a biodegradable material and provide bacterial viability. An example of these 
polymers is PVA - poly (vinyl alcohol), characterized by being soluble in water, 
chemically stable, and of low cost. Studies have shown that its use the use of this 
material alone [102] or associated with other biomaterials [103] is satisfactory while 
maintaining the viability of probiotic microorganisms. Poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene 
glycol) (PEG), poly(ethylene oxide) (PEO), and poly(vinyl pyrrolidone) (PVP) are 
other synthetic polymers used for encapsulation of probiotics synthetic polymers 
used for encapsulation of probiotics [84]. The use of these polymers is linked to the 
technique of producing fibers through electrospinning.
All of these alternatives mentioned aim to encapsulate probiotics for intestinal 
delivery. Although they can be applied to other tissues of the body, the data in the 
literature are incipient and need to be better analyzed for application in the treat-
ment of other infections, such as those discussed in the next topic.
5. Prevention and treatment of infection with probiotics
The resistance of pathogenic microorganisms to synthetic antimicrobials and, 
consequently, the ineffectiveness of conventional therapies and recurrence of 
infections reflects the need to seek alternative and/or supplementary methods in 
the treatment protocols [104]. Probiotics are one of the methods and are considered 
promising, as they provide satisfactory results when facing infections of a bacte-
rial, fungal and viral nature, whether in the intestinal, urinary, respiratory, female 
genital tracts, and in the oral cavity. In addition, it is safe and does not promote 
adverse effects on the human body [105, 106]. Figure 1 schematizes the delivery 
of microencapsulated probiotic microorganisms in an epithelium colonized by 
pathogenic microorganisms for the treatment of an infection.
One indication of probiotics refers to the treatment of Helicobacter pylori 
infection, which is one of the most common chronic bacterial infections in 
humans, with approximately 4.4 billion infected individuals worldwide in  
2015 [107]. H. pylori infection is associated with the development of gastric 
cancer, which represents one of the main global causes of cancer-related deaths 
[108, 109]. The treatment of H. pylori infection is based on its eradication, with 
the use of antibiotics, such as amoxicillin, clarithromycin, and metronidazole. 
However, antibiotic therapy promotes an imbalance in the intestinal microbiota 
and increased levels of resistant bacteria [110], as well as species associated with 
persistent gastric inflammation and gastric carcinogenesis [111]. This situation 
justifies probiotic supplementation, aiming to reduce undesirable changes in the 
intestinal microbiota, promote the eradication of H. pylori [108, 112], produce 
significant improvements in gastrointestinal symptoms, and, consequently, in 
the quality of life of individuals [108, 109]. The combination of probiotics with 
antibiotic therapy for the eradication of H. pylori was suggested in the Thailand 
Consensus, held in 2015 [110].
Probiotics, in addition to reducing the density of H. pylori, promote immune 
responses with reduced inflammatory status [112–115], significantly reduce adverse 
events related to antibiotic treatment, and improve patient compliance [109, 116]. 
Despite this evidence, it was highlighted in the Thailand Consensus, that most 
studies that evaluated the effects of probiotics on the eradication of H. pylori are of 
poor quality, compromising general recommendations. It has been suggested that 
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further studies should be carried out to determine the best strain, the ideal dose, the 
duration of treatment, effectiveness, contraindications, and cost–benefit [110].
Probiotics are also indicated to reduce or prevent diarrhea associated with 
antibiotics and infections by Clostridium difficile, common in hospitalized patients 
[117, 118] and the elderly [119]. In children, its effectiveness in preventing antibi-
otic-associated diarrhea [120] and in treatment for acute gastroenteritis has not 
been confirmed, despite reducing the duration of hospitalization [121]. The use of 
probiotics in the treatment of infections by Enterobacteriaceae producing extended-
spectrum β-lactamase has also been discussed. However, the results are incipient to 
indicate its use in eradication therapy in patients with prolonged intestinal trans-
port of Enterobacteriaceae [122].
Some studies have suggested that supplementation with probiotics can improve 
the host’s innate and acquired immune response, promoting a protective effect 
against respiratory infections [46, 123, 124]. The increase in the population of T 
cells, more precisely CD4 and CD8, is one of the most important mechanisms of 
the anti-infection effect of probiotics [125, 126]. Oral probiotics, when used in 
children, in addition to improving intestinal microecological balance can reduce the 
frequency of respiratory tract infections [89], mostly caused by viruses, such as the 
coronavirus [127], influenza [128], and bacteria, such as Streptococcus pneumoniae) 
[129]. Several studies have found that probiotics reduce episodes of acute respira-
tory tract infections in children, adults, the elderly, and athletes [89, 125, 126, 130, 
131], proving its beneficial effect in these populations, with no reports of adverse 
effects in children [131].
The high recurrence of urinary tract infections in children [132] and the 
possibility of developing microbial resistance to drugs used against this disease 
have justified research with non-antibiotic alternatives, such as the use of 
probiotics for the prevention of recurrent urinary infections in this population 
Figure 1. 
Microencapsulated probiotics being delivered for the treatment of infection in epithelial tissue. Note that after 
the exit of the microorganisms from the micelle there is the colonization of the region and release of bacteriocins 
that in addition to acting as antimicrobials, stimulate the host’s immune system.
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[133]. Probiotics appear to prevent recurrent urinary infections by contributing 
to the recovery and maintenance of microbiomes, by reducing the adherence, 
growth, and colonization of infectious pathogens in the urinary tract, in addition 
to improving host defenses, and attenuating or eliminating inflammation [105, 
134–144]. Unlike the beneficial role of the use of probiotics in preventing urinary 
infections in children [132], it appears to have no protective effect in adults with 
severe spinal injuries, who have recurrent urinary infections [145], as well as in 
healthy young women [146].
Regarding the genital tract, the administration of probiotics, alone or as adjunc-
tive therapy to the use of conventional antimicrobials, demonstrates success in the 
treatment of infections such as bacterial vaginosis and vulvovaginal candidiasis, 
common and recurrent infections in women of reproductive age. These infections 
that produce abnormal vaginal discharge, itching, vulvar odor, are associated with 
important health complications, such as the increased transmission of sexual infec-
tions, risk of premature birth, and pelvic inflammation, with negative impacts on 
quality of life [138, 147–149].
In infections that affect the mouth, candidiasis is also one of the most prevalent 
diseases, especially when local factors are predisposing the installation of the infec-
tion. Probiotics have been suggested for the treatment of oral candidiasis because 
they reduce the population of Candida ssp. [150], the course of treatment with 
conventional antifungal therapies [151], and the severity of clinical manifestations 
of the infection associated with prosthetic stomatitis [152, 153], including asymp-
tomatic [62]. Besides, the immunological and antimicrobial potential of probiotics 
also can be used in the treatment of periodontal disease killing periodontopatho-
gens, as Porphyromona gingivalis, and promoting the expression of some favorable 
immunoregulatory effects [154]. In summary, probiotics favor oral health, increas-
ing fluids in the mucosa, reducing the accumulation of dental biofilm and gingival 
inflammation, improving the clinical signs characteristic of periodontal infection, 
such as redness and swelling [63, 155, 156].
Studies show beneficial effects of the combination of probiotics in the treatment 
regimen for different infections, with improvements in the clinical condition and 
patient adherence to treatment. Although, researchers warn of the need for further 
studies to define the best treatment protocol, including the determination of effects, 
contraindications, and cost–benefit [110].
6. Concluding remarks
Today’s society is experiencing a public health problem related to an exponential 
increase in microbial resistance, compared to the slow evolution of new drug devel-
opment. The human organism is attacked daily by countless pathogenic microor-
ganisms, many of which cause lethal infections. The use of alternative therapies, 
alone or as an adjunct to antibiotics, is a reality. Concerning the use of probiotics, its 
effectiveness in modifying the microbial is unquestionable, either by the produc-
tion of antimicrobial bacteriocins or by the modulation of the immune system. 
Nonetheless, there is no consensus or standardization for the clinical use of probiot-
ics for the treatment of infectious diseases, except its use for the recomposition of 
the intestinal microbiota. Moreover, two important challenges need to be overcome: 
the standardization of carriers to deliver these microorganisms effectively to the 
treatment site and the definition of important factors, such as the mechanism of 
action, standardization of inoculum, and therapeutic protocols, based clinical 
trials. Thus, although promising, widespread antimicrobial therapy with probiotics 
is not yet a reality for clinical practice.
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